GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Net Change in Cash

CSL (CMXHF) Net Change in Cash : $-446 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CSL Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

CSL's Net Change in Cash for the six months ended in Dec. 2023 was $-498 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-446 Mil.

CSL Net Change in Cash Historical Data

The historical data trend for CSL's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Net Change in Cash Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -154.90 493.50 578.80 8,604.30 -8,825.00

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,519.30 4,085.00 -8,876.70 51.70 -498.00

CSL Net Change in Cash Calculation

CSL's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2601+-11843+456+-39
=-8,825

CSL's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1069+-702+-814+-51
=-498

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-446 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Net Change in Cash Related Terms

Thank you for viewing the detailed overview of CSL's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CMXHF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Net Change in Cash
Comparable Companies
ASX:TLX ASX:NEU ASX:IMU ASX:CU6 ASX:CUV ASX:MSB ASX:OPT ASX:IMM ASX:BOT ASX:PYC OCSE:NOVO B VRTX REGN XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX OCSE:GMAB
Traded in Other Exchanges
CSLLY:USA CSJ:Germany CSL:Australia
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
Website
https://www.csl.com
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.